PetVivo Holdings, Inc., in cooperation with its wholly-owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI, Inc., a leading provider of medical devices and biomedical therapeutics for equines and companion animals, has announced a virtual investor event titled "What Veterinarians Are Seeing and How Access Is Expanding." The event is scheduled for Tuesday, June 16, 2026, at 1 p.m. ET and is designed for both new and current investors.

Event Overview

The virtual event will provide attendees with an accessible overview of the company's business operations, with a particular focus on Spryng® with OsteoCushion® Technology, real-world veterinary field feedback, and PetVivo's ongoing initiatives to broaden market reach through sales and distribution relationships. The company expects the event to offer investors a firsthand look at how veterinarians are evaluating and using Spryng in clinical practice.

Featured Speakers

The moderator-led discussion will feature the following participants:

How to Attend

Investors can tune in to the live event through the following platforms:

• YouTube: https://www.youtube.com/live/QLFfsfCpE1U?si=ItU-PWgNUKsQ2tkQ
• LinkedIn: https://www.linkedin.com/events/7466155223904890880?viewAsMember=true

A replay of the event is expected to be available following the webcast. Investors can also visit the company's Investor Relations page at https://www.petvivo.com/investors for additional company information, financial materials, and updates.

About PetVivo Holdings, Inc.

PetVivo Holdings, Inc., in cooperation with its wholly-owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI, Inc., is an emerging biomedical device company focused on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for companion animals. The company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time-efficient manner, with an emphasis on the accelerated timeline to revenues for veterinary medical devices.

PetVivo maintains a robust pipeline of products for the treatment of animals and people, protected by a portfolio of twelve patents and six trade secrets covering its biomaterials, products, production processes, and methods of use. The company's lead products include:

• SPRYNG® with OsteoCushion® Technology — a veterinarian-administered, intra-articular injection for the management of lameness and other joint-related afflictions, including osteoarthritis, in cats, dogs, and horses
• PrecisePRP® — a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians

Both products are currently available for commercial sale.